Glow LifeTech (GLOW) AI Stock Analysis

• Market Cap: C$9.96M
• Dividend Yield: N/A
• Average Volume (3M): 266.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: 239.98%
• EPS Growth: 39.01%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 181,160,580
• 10 Day Avg. Volume: 165,602
• 30 Day Avg. Volume: 266,047
• PEG Ratio: -0.30
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 7.42
• P/FCF Ratio: -4.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.05 ▼(-11.67% Downside)

The score is primarily held back by weak financial performance: heavy operating losses and negative free cash flow despite improving revenue and gross margin. Technicals also weigh on the score with price below major moving averages and negative MACD, while valuation is difficult to assess given negative earnings and no dividend data.

Positive Factors

Revenue growth and rising gross margin

Sustained TTM revenue growth (+27.9%) combined with a materially improved gross margin (~51.7%) signals stronger product commercialization and unit economics. Over 2–6 months this supports scaling potential and lowers the revenue threshold needed to reach operating break-even if cost discipline continues.

Modest leverage reduces financial fragility

A low debt-to-equity ratio (~0.20) means the company faces limited interest and refinancing pressure versus highly leveraged peers. This structural conservatism gives flexibility to absorb near-term losses, extend runway, and pursue strategic investments without immediate solvency risk.

Improving operating cash flow trend

Operating cash flow has materially improved versus the prior period, showing progress toward positive cash generation. If this trajectory persists, the company can reduce reliance on external funding, improving financial resilience and enabling reinvestment in growth over the coming months.

Negative Factors

Large operating and net losses

Very wide operating and net losses indicate the business model is not yet profitable and fixed costs substantially exceed current revenues. Persisting losses over several quarters will deplete resources and require either rapid revenue scale-up or restructuring to become sustainable.

Negative free cash flow and cash burn

Ongoing negative free cash flow and a sharp FCF decline versus prior periods mean the company is not self-funding operations. Structurally, this necessitates external capital to sustain operations, raising dilution or financing risk and constraining strategic choices over the medium term.

Very weak returns and past equity volatility

Extremely negative ROE and prior episodes of negative equity point to poor capital efficiency and balance-sheet instability. This legacy weakness can limit ability to attract long-term financing or strategic partners and raises downside risk if operational improvement stalls.

Glow LifeTech Business Overview & Revenue Model

Company Description

Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical and cannabis nutrient delivery technology; and a cannabis Smart Consumption System to assist users and patients to store, journal, control, consume, and manage cannabis related products. The company has the exclusive North American rights for the production, sale, and distribution rights for the certain micellization technology for cannabis and hemp derived ingredients, curcumin, vitamin K, and iron. It also engages in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility. The company was incorporated in 2018 and is based in Toronto, Canada.

How the Company Makes Money

Glow LifeTech generates revenue through multiple streams, primarily from the sale of its health supplements and skincare products through both online and offline retail channels. The company operates a direct-to-consumer e-commerce platform, which allows it to capture higher margins by selling directly to customers. Additionally, GLOW has established partnerships with various health and wellness retailers, providing its products in physical stores and expanding its market reach. The company also engages in subscription-based models for certain product lines, ensuring consistent revenue flow. Furthermore, GLOW invests in research and development to innovate new products, which can lead to increased sales and market share, thereby enhancing its financial performance.

Glow LifeTech Financial Statement Overview

Summary

Revenue is growing (TTM ~C$1.85M, +27.9%) and gross margin improved (~51.7%), but the company remains deeply unprofitable (operating margin ~-66%, net margin ~-123%) with ongoing cash burn (TTM operating cash flow ~-C$0.37M; free cash flow ~-C$0.42M). Balance sheet leverage is modest (debt-to-equity ~0.20), yet returns are sharply negative (ROE ~-96%).

Income Statement

TTM (Trailing-Twelve-Months) revenue increased to ~C$1.85M (27.9% growth) and gross margin improved to ~51.7%, showing better commercialization traction versus prior years. However, profitability remains very weak with sizable operating losses (TTM operating margin about -66%) and a deeply negative net margin (~-123%), indicating the cost base is still far ahead of the current revenue scale.

Balance Sheet

Leverage is modest, with TTM debt-to-equity around 0.20 (and ~0.16 in 2024), which reduces financial risk versus more highly levered peers. That said, returns remain sharply negative (TTM return on equity ~-96%), reflecting ongoing losses; the company also previously reported negative equity (2023), highlighting historical balance-sheet volatility even though equity is now positive.

Cash Flow

Cash burn continues, with TTM operating cash flow around -C$0.37M and free cash flow around -C$0.42M, although this is a notable improvement versus 2024 (operating cash flow about -C$1.35M). Free cash flow declined versus the prior period (TTM growth ~-61%), and cash generation is not yet self-funding, leaving the business reliant on external capital if losses persist.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.85M	836.19K	43.93K	0.00	0.00	0.00
Gross Profit	957.52K	591.00K	-759.18K	-263.26K	-43.39K	0.00
EBITDA	-973.91K	-1.24M	-1.31M	-1.92M	-4.59M	-153.00K
Net Income	-2.28M	-2.66M	-1.59M	-2.24M	-11.31M	-153.00K
Balance Sheet
Total Assets	3.70M	3.72M	1.91M	2.31M	3.76M	2.60K
Cash, Cash Equivalents and Short-Term Investments	1.12M	1.29M	34.00	75.19K	746.02K	1.80K
Total Debt	435.15K	404.08K	171.75K	147.36K	39.93K	6.40K
Total Liabilities	1.48M	1.15M	2.35M	1.14M	328.03K	315.57K
Stockholders Equity	2.22M	2.57M	-433.12K	1.16M	3.44M	-312.97K
Cash Flow
Free Cash Flow	-422.96K	-1.36M	-490.86K	-1.36M	-3.62M	-18.65K
Operating Cash Flow	-372.69K	-1.35M	-417.26K	-1.30M	-3.18M	-18.65K
Investing Cash Flow	-51.98K	16.70K	-60.91K	18.31K	-541.41K	-1.36K
Financing Cash Flow	657.99K	2.62M	445.01K	491.44K	4.59M	2.93K

Glow LifeTech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:GLOW.

Glow LifeTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDMA	49 Neutral	C$10.89M	-4.98	-85.96%	―	-72.51%	-170.13%
PREV	42 Neutral	C$11.74M	-3.64	21.59%	―	―	-120.00%
GLOW	41 Neutral	C$9.96M	-4.04	-153.85%	―	239.98%	39.01%
KNE	41 Neutral	C$6.36M	-2.87	―	―	―	―

Glow LifeTech Corporate Events

Glow Lifetech Pushes National Cannabis Expansion with Manitoba Entry and New Brunswick Portfolio Boost

Glow Lifetech Corp. is extending its MOD and .decimal cannabis brands into Manitoba and broadening its product portfolio in New Brunswick as part of its ongoing national expansion across Canada. The company has secured eight initial product listings for Manitoba’s cannabis retail market and plans to launch the expanded New Brunswick offering in spring 2026, moves that underscore growing demand from provincial distributors and retailers for its differentiated product formats and validate the scalability of its commercial model, while reinforcing its strategy of disciplined, stepwise growth from a strong base in Ontario.

The most recent analyst rating on (TSE:GLOW) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on Glow LifeTech stock, see the TSE:GLOW Stock Forecast page.

Glow Lifetech Enters Canadian Medical Cannabis Market with National Mendo Launch

Glow Lifetech has entered the Canadian medical cannabis market by launching its MOD and .decimal product portfolio on the national Mendo Medical Cannabis platform, making 14 SKUs of its next-generation cannabis products available to registered medical patients, including veterans, across the country. The move diversifies Glow’s distribution channels beyond provincial retail, strengthens its partnership with a leading medical-focused provider and underscores the scalability of its technology-driven product platforms, positioning the company to reach a broader customer base while emphasizing consistency, dose control and operational efficiency.

The most recent analyst rating on (TSE:GLOW) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on Glow LifeTech stock, see the TSE:GLOW Stock Forecast page.

Glow Lifetech Achieves Record Q3 2025 Results and Positive Cash Flow

Glow Lifetech Corp. reported a record-breaking Q3 2025 with a 193% year-over-year revenue growth and achieved its first positive cash flow from operations. This milestone reflects the company’s strong commercial momentum, disciplined cost management, and improved financial strength, positioning it for continued growth and profitability. The company expanded its market presence by adding new listings with major retailers in Ontario and launching products in Saskatchewan, while maintaining its leadership in the oils category with its MOD™ brand. Glow’s strategic focus on product innovation and national expansion supports its long-term growth trajectory into 2026.

Glow Lifetech Achieves Debt-Free Status, Strengthens Financial Position

Glow Lifetech Corp has achieved a debt-free status, marking a significant milestone in its financial management strategy. By eliminating over $1.4 million in debt, the company has strengthened its balance sheet, reduced interest expenses, and enhanced its financial flexibility, positioning itself for sustainable long-term growth and profitability. This financial achievement allows Glow to focus on advancing its national growth strategy and scaling its category-leading brands, thereby creating long-term value for shareholders.